Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to electroCore, Inc. (Nasdaq: ECOR) SEC filings, offering a detailed view of how the company reports its activities as a commercial-stage bioelectronic medicine and wellness business. electroCore focuses on non-invasive neuromodulation and bioelectronic technologies, including its gammaCore nVNS and Quell neurostimulator prescription products and its Truvaga and TAC-STIM wellness and performance devices.
Through forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of electroCore’s business, risk factors, financial condition, and operating results. Current reports on Form 8-K, several of which are referenced in the input data, disclose material events including quarterly financial results, private placements of common stock to satisfy specific obligations, and changes in the composition and leadership of the board of directors.
Other filings may cover topics such as stockholder votes on charter amendments, advisory votes on executive compensation, and the appointment of new independent directors or committee members. Together, these documents outline electroCore’s governance practices, capital structure developments, and key financial metrics over time.
On Stock Titan, these SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the contents of lengthy reports, highlight important sections of 10-K and 10-Q filings, and clarify the implications of Form 8-K disclosures. Users can also review insider-related filings such as Form 4, where available, to see reported transactions by directors and officers. This combination of primary documents and AI-generated insights is intended to make electroCore’s regulatory record more accessible to a wide range of readers.
Thomas J. Errico, a director of electroCore, Inc. (ECOR), purchased 15,000 common shares on 08/11/2025 at a weighted-average price of $4.47 per share. After the purchase he beneficially owns 281,401 shares, consisting of 217,051 shares owned directly, 1,296 and 11,000 shares held in two trusts, 50,672 vested Deferred Stock Units (DSUs), and 1,382 DSUs that vest monthly through September 3, 2025 (with full vesting earlier upon specified events). The filer notes a price range of $4.34 to $4.55 and will provide a breakdown of purchases on request.
Daniel S. Goldberger, Chief Executive Officer and director of electroCore, purchased 1,000 shares of common stock on 08/11/2025 at a weighted-average price of $4.23 per share (purchase prices ranged from $4.225 to $4.25). After the purchase he beneficially owns 291,565 shares. The filing notes that this total includes previously issued restricted stock units of 75,000 (25,000 vested; 50,000 vesting one-half on January 16, 2026 and January 16, 2027), 50,000 (33,333 vested; 16,667 vesting August 4, 2026), and 40,000 (vesting in one-third increments on January 18, 2026, January 18, 2027, and January 18, 2028).
electroCore, Inc. (ECOR) – Form 4 filing: On 08/01/2025 director James C. Theofilos was granted 22,156 restricted stock units (RSUs) under the company’s 2018 Omnibus Equity Compensation Plan. Each RSU converts into one common share and vests in 12 equal quarterly installments over 36 months. The award was recorded at $0 purchase price, indicating an incentive grant rather than an open-market buy. After the transaction, Theofilos’ direct beneficial ownership increased to 23,547 shares, consisting of 22,156 unvested RSUs and 1,391 previously held common shares. No shares were sold, no derivative securities were reported, and the form was signed on 08/05/2025.